The Latest Breaking News from Shockwave Medical

Shockwave Medical is being added to the S&P 400 Index after several quarters of strong growth, thanks to its newest product.

A Relative Strength Rating upgrade for Shockwave Medical shows improving technical performance.

According to Benzinga Pro, during Q1, ShockWave Medical (NASDAQ:SWAV) earned $14.52 million, a 12.2% increase from the preceding quarter. ShockWave Medical also posted a total of $93.63 million in sales, a 11.22% increase since Q4.

Over the past 3 months, 6 analysts have published their opinion on ShockWave Medical (NASDAQ:SWAV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Shockwave Medical Inc (NASDAQ:SWAV) reported first-quarter revenue of $93.63 million, an increase of 193.5% year-over-year, beating the consensus of $86.41 million. The gross margin for Q1 expanded to 86.2% from 75.3% in 1Q21. The operating income for the quarter totaled $15.37 million versus a loss of $(17.48) million a year ago. EPS…

ShockWave Medical (NASDAQ:SWAV) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ShockWave Medical will report an earnings per share (EPS) of $0.18.

The Dow Jones took a dive as fears over the economy caused stocks to swoon. HCA Healthcare stock collapsed. Verizon also plummeted.

The Dow Jones inched higher as stocks fought off lows. Visa stock was a top blue performer. Amazon stock gained despite a unionization vote.

Shockwave Medical Inc's (NASDAQ: SWAV)